What question did this study set out to answer?

To evaluate and compare the safety and efficacy of catheter ablation versus antiarrhythmic drug therapy in patients with structural heart disease experiencing ventricular tachycardia.

January 10, 2023CureusOpen Access

The Effectiveness of Catheter Ablation in the Management of Ventricular Tachycardia in Comparison With Antiarrhythmic Drugs in Patients With Structural Heart Disease: A Meta-Analysis

View Full Paper

Ask AI

Bookmark

Why the study?

To compare the safety and efficacy of catheter ablation versus antiarrhythmic drugs in the management of ventricular tachycardia in patients with structural heart diseases.

Does catheter ablation reduce recurrence of ventricular tachycardia and mortality in patients with structural heart disease compared to antiarrhythmic drugs?

Comparison

Catheter ablation vs antiarrhythmic drugs

Authors

JKJithin KaredathAndhra University AVAntonia Lisseth Valle VillatoroUniversity of Delhi SFSana FaisalUniversity of Delhi

Discussion

Member takes

Implication

Similar VT recurrence and mortality risks support either strategy in structural heart disease; confirms equipoise and leaves optimal choice open for trials.

Key Points

To evaluate and compare the safety and efficacy of catheter ablation versus antiarrhythmic drug therapy in patients with structural heart disease experiencing ventricular tachycardia.
Conducted a systematic search across PubMed, Cochrane, and EMBASE databases from inception to November 30, 2022.
Identified and analyzed three randomized controlled trials comparing catheter ablation with antiarrhythmic medications for efficacy and safety outcomes.
No significant difference was observed between catheter ablation and antiarrhythmic drugs for ventricular tachycardia recurrence (RR: 0.94, 95% CI: 0.72–1.24, p=0.67), all-cause mortality (RR: 0.99, 95% CI: 0.67–1.46, p=0.98), or cardiovascular mortality (RR: 0.90, 95% CI: 0.56–1.45, p=0.67).
Rates of ICD shocks (RR: 0.99, 95% CI: 0.76–1.29, p=0.93) and cardiac-related hospitalizations (RR: 0.77, 95% CI: 0.55–1.07, p=0.12) did not differ significantly between the groups.
Catheter ablation resulted in a significantly lower risk of treatment-related adverse events compared to antiarrhythmic therapy (RR: 0.44, 95% CI: 0.29–0.67, p=0.0001).

Structured PICO

Does catheter ablation reduce recurrence of ventricular tachycardia and mortality in patients with structural heart disease compared to antiarrhythmic drugs?

Population

Patients with structural heart disease who had ventricular tachycardia (meta-analysis of 3 RCTs)

Intervention

Catheter ablation

Comparator

Antiarrhythmic drugs (AADs)

Outcome

Recurrence of ventricular tachycardia at follow-up, all-cause mortality, and cardiovascular mortalityhard clinical

In patients with structural heart disease and ventricular tachycardia, catheter ablation provides similar efficacy to antiarrhythmic drugs for preventing VT recurrence and mortality, but with a significantly lower risk of treatment-related adverse events.

Cite This Study

Karedath et al. (2023) studied this question.

synapsesocial.com/papers/6a0ed80625c30b2cc7f9d3cd https://doi.org/10.7759/cureus.33608

Topics

Ventricular arrhythmias AF ablation outcomes

View Full Paper

Ask AI

Bookmark

Implication

Similar VT recurrence and mortality risks support either strategy in structural heart disease; confirms equipoise and leaves optimal choice open for trials.

The Effectiveness of Catheter Ablation in the Management of Ventricular Tachycardia in Comparison With Antiarrhythmic Drugs in Patients With Structural Heart Disease: A Meta-Analysis

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

The Effectiveness of Catheter Ablation in the Management of Ventricular Tachycardia in Comparison With Antiarrhythmic Drugs in Patients With Structural Heart Disease: A Meta-Analysis

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider